Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, No.1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China.
Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.
World J Surg Oncol. 2024 Jan 23;22(1):26. doi: 10.1186/s12957-023-03293-2.
To explore the risk factors for disease progression after initial treatment of type B thymomas using a predictive nomogram model.
A single-center retrospective study of patients with type B thymoma was performed. The Cox proportional hazard model was used for univariate and multivariate analyses. Variables with statistical and clinical significance in the multivariate Cox regression were integrated into a nomogram to establish a predictive model for disease progression.
A total of 353 cases with type B thymoma were retrieved between January 2012 and December 2021. The median follow-up was 58 months (range: 1-128 months). The 10-year progression-free survival (PFS) was 91.8%. The final nomogram model included R0 resection status and Masaoka stage, with a concordance index of 0.880. Non-R0 resection and advanced Masaoka stage were negative prognostic factors for disease progression (p < 0.001). No benefits of postoperative radiotherapy (PORT) were observed in patients with advanced stage and non-R0 resection (p = 0.114 and 0.284, respectively).
The best treatment strategy for type B thymoma is the detection and achievement of R0 resection as early as possible. Long-term follow-up is necessary, especially for patients with advanced Masaoka stage and who have not achieved R0 resection. No prognostic benefits were observed for PORT.
利用预测列线图模型探讨 B 型胸腺瘤初始治疗后疾病进展的危险因素。
对 B 型胸腺瘤患者进行单中心回顾性研究。采用 Cox 比例风险模型进行单因素和多因素分析。将多因素 Cox 回归中具有统计学和临床意义的变量整合到列线图中,建立疾病进展的预测模型。
共纳入 2012 年 1 月至 2021 年 12 月间 353 例 B 型胸腺瘤患者。中位随访时间为 58 个月(范围:1-128 个月)。10 年无进展生存率(PFS)为 91.8%。最终的列线图模型包括 R0 切除状态和 Masaoka 分期,一致性指数为 0.880。非 R0 切除和晚期 Masaoka 分期是疾病进展的负预后因素(p<0.001)。对于晚期和非 R0 切除的患者,术后放疗(PORT)并未带来获益(p=0.114 和 0.284)。
B 型胸腺瘤的最佳治疗策略是尽早发现并实现 R0 切除。需要长期随访,特别是对于晚期 Masaoka 分期和未达到 R0 切除的患者。PORT 并未带来预后获益。